 <h1>Sulfazine Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>sulfasalazine</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about sulfasalazine. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Sulfazine.</p><h2>In Summary</h2><p><b>Common side effects of Sulfazine include:</b> gastric distress, headache, nausea, oligospermia, vomiting, and anorexia. <b>Other side effects include:</b> fever.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to sulfasalazine: oral tablet, oral tablet enteric coated</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, sulfasalazine (the active ingredient contained in Sulfazine) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking sulfasalazine:</p><p>
<i>More common</i>
</p><ul>
<li>Aching of joints</li>
<li>fever</li>
<li>headache (continuing)</li>
<li>increased sensitivity of the skin to sunlight</li>
<li>skin rash or itching</li>
<li>vomiting</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Back, leg, or stomach pains</li>
<li>bleeding gums</li>
<li>bluish color of the fingernails, lips, skin, palms, or nail beds</li>
<li>chills</li>
<li>dark urine</li>
<li>difficulty breathing</li>
<li>fever</li>
<li>general body swelling</li>
<li>headache</li>
<li>loss of appetite</li>
<li>nausea</li>
<li>nosebleeds</li>
<li>pale skin</li>
<li>sore throat</li>
<li>troubled breathing with exertion</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>yellowing of the eyes or skin</li>
</ul><p>
<i>Less common or rare</i>
</p><ul>
<li>Aching of muscles</li>
<li>black, tarry stools</li>
<li>blistering, peeling, or loosening of the skin</li>
<li>bloating</li>
<li>blood in the urine or stools</li>
<li>bloody diarrhea</li>
<li>bluish fingernails, lips, or skin</li>
<li>chest pain</li>
<li>constipation</li>
<li>cough</li>
<li>difficulty with swallowing</li>
<li>dizziness</li>
<li>fainting spells</li>
<li>fast heartbeat</li>
<li>general feeling of discomfort or illness</li>
<li>general tiredness and weakness</li>
<li>hives</li>
<li>indigestion</li>
<li>inflammation of the joints</li>
<li>irregular heartbeat</li>
<li>light-colored stools</li>
<li>muscle aches</li>
<li>muscle cramps or spasms</li>
<li>muscle pain or stiffness</li>
<li>painful or difficult urination</li>
<li>pains in the stomach, side, or abdomen, possibly radiating to the back</li>
<li>pinpoint red spots on the skin</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>rash</li>
<li>red skin lesions, often with a purple center</li>
<li>red, irritated eyes</li>
<li>redness, blistering, peeling, or loosening of the skin</li>
<li>sores, ulcers, or white spots in the mouth or on the lips</li>
<li>swollen or painful glands</li>
<li>tightness in the chest</li>
<li>upper right abdominal or stomach pain</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of sulfasalazine may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Abdominal or stomach pain or upset</li>
<li>decreased weight</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Welts</li>
</ul><p>
<i>Less common or rare</i>
</p><ul>
<li>Discoloration of the skin or urine</li>
<li>hair loss or thinning of the hair</li>
<li>swelling or inflammation of the mouth</li>
</ul><p>
<!-- end oral tablet, oral tablet enteric coated --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to sulfasalazine: compounding powder, oral delayed release tablet, oral tablet</i></p><h3>General</h3><p>The most common side effects reported were anorexia, headache, nausea, vomiting, gastric distress, elevated temperature, erythema, pruritus, rash, loss of appetite, and reversible oligospermia.  Less common side effects included urticaria, fever, Heinz body anemia, hemolytic anemia, and cyanosis.  Frequency of side effects increased with daily doses of 4 g or more, or total serum sulfapyridine levels above 50 mcg/mL.</p>
<p></p>
<p>The use of enteric-coated preparations may decrease gastrointestinal side effects.</p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 33%), vomiting (up to 33%), gastric distress (about 33%), dyspepsia (13%)</p>
<p><b>Common</b> (1% to 10%): Abdominal pain, diarrhea, stomatitis</p>
<p><b>Frequency not reported</b>: Impaired folic acid absorption, impaired digoxin absorption, neutropenic enterocolitis, hemorrhagic colitis, bloody diarrhea, necrotizing pancreatitis</p>
<p><b>Postmarketing reports</b>: Pseudomembranous colitis, pancreatitis, worsening ulcerative colitis, parotitis<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Transverse myelitis developed in 1 patient after receiving sulfasalazine (the active ingredient contained in Sulfazine) for 2 years.  All symptoms resolved within 2 months after discontinuing sulfasalazine.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Headache (up to 33%)</p>
<p><b>Common</b> (1% to 10%): Dizziness, taste disorders, tinnitus</p>
<p><b>Uncommon</b> (0.1% to 1%): Convulsions, vertigo</p>
<p><b>Frequency not reported</b>: Meningitis, neuropathy, transverse myelitis, transient lesions of the posterior spinal column, cauda equina syndrome, Guillain-Barre syndrome, hearing loss, drowsiness, neurotoxicity, dysphasia, acute encephalopathy, monoparesis, cerebrospinal fluid abnormalities, altered taste, peripheral neuritis</p>
<p><b>Postmarketing reports</b>: Aseptic meningitis, ataxia, encephalopathy, peripheral neuropathy, smell disorders<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Hypoglycemia has been reported rarely in patients using sulfonamides.</p><p><b>Very common</b> (10% or more): Anorexia (about 33%)</p>
<p><b>Rare</b> (less than 0.1%): Hypoglycemia</p>
<p><b>Postmarketing reports</b>: Folate deficiency, loss of appetite</p><h3>Genitourinary</h3><p>Diuresis has been reported rarely in patients using sulfonamides.</p>
<p></p>
<p>Infertility appeared to be reversible upon drug discontinuation.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Reversible oligospermia (about 33%)</p>
<p><b>Common</b> (1% to 10%): Proteinuria</p>
<p><b>Rare</b> (less than 0.1%): Impotence, diuresis</p>
<p><b>Frequency not reported</b>: Decreased motility, abnormal sperm penetration (sometimes resulted in infertility), urinary tract infections, urine discoloration</p>
<p><b>Postmarketing reports</b>: Hematuria, crystalluria<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (up to 13%)</p>
<p><b>Common</b> (1% to 10%): Pruritus, urticaria</p>
<p><b>Uncommon</b> (0.1% to 1%): Alopecia</p>
<p><b>Frequency not reported</b>: Toxic epidermal necrolysis (Lyell's syndrome), skin discoloration, erythema multiforme, parapsoriasis varioliformis acuta (Mucha-Haberman syndrome), generalized skin eruptions, petechiae</p>
<p><b>Postmarketing reports</b>: Angioedema, purpura, epidermal necrolysis (Lyell's syndrome), Stevens-Johnson syndrome, drug rash with eosinophilia and systemic symptoms (DRESS), toxic pustuloderma, erythema, exanthema, exfoliative dermatitis, periorbital edema, lichen planus, photosensitivity<sup>[Ref]</sup></p><p>Angioedema was reported during postmarketing experience with the use of products containing or metabolized to mesalamine.</p>
<p></p>
<p>The risk of Stevens-Johnson syndrome or toxic epidermal necrolysis increased largely with the use of sulfonamides; however, these phenomena were rare as a whole.<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Immunoglobulin suppression (10%)</p>
<p><b>Frequency not reported</b>: Drug-induced systemic lupus erythematosus (SLE)</p>
<p><b>Postmarketing reports</b>: Kawasaki-like syndrome with hepatic function changes, induction of autoantibodies<sup>[Ref]</sup></p><p>Immunoglobulin suppression was slowly reversible and rarely accompanied by clinical findings.</p>
<p></p>
<p>In most cases of sulfasalazine-induced SLE, patients received the drug for greater than 1 year.  Patients most commonly developed arthralgias and pleuritic chest pain.  Generally, these patients had a positive ANA, anti-DNA antibody titer, and were slow acetylators of sulfonamides.  Symptoms typically resolved over several weeks to several months.</p>
<p></p>
<p>At least 1 case of Kawasaki-like syndrome with hepatic function changes was reported during postmarketing experience with the use of products containing or metabolized to mesalamine.<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Hepatitis associated with sulfasalazine (the active ingredient contained in Sulfazine) often developed 2 to 4 weeks after therapy was initiated, although hypersensitivity hepatitis has been reported after longer periods of therapy.  Associated rash usually progressed to desquamation.  Liver biopsy has shown necrosis and infiltration with moderate number of inflammatory cells.  Noncaseating granulomas have also been seen.  Hepatitis generally resolved over several weeks after therapy discontinuation, although some patients progressed to fulminant hepatic failure.</p>
<p></p>
<p>Hepatitis has been reported in patients with sulfasalazine hypersensitivity.  Some of these cases were fatal.</p>
<p></p>
<p>Side effects listed as postmarketing reports were reported during postmarketing experience with the use of products containing or metabolized to mesalamine.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Abnormal liver function tests</p>
<p><b>Uncommon</b> (0.1% to 1%): Elevated liver enzymes</p>
<p><b>Frequency not reported</b>: Hepatic necrosis</p>
<p><b>Postmarketing reports</b>: Hepatotoxicity (some cases were fatal), including elevated liver function tests (SGOT/AST, SGPT/ALT, GGT, LDH, alkaline phosphatase, bilirubin), jaundice, cholestatic jaundice, cirrhosis, cholestatic hepatitis, cholestasis, possible hepatocellular damage (including liver necrosis and liver failure); Kawasaki-like syndrome with hepatic function changes; fulminant hepatitis; hepatitis; hepatic failure<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Hemolytic anemia, Heinz body anemia, leukopenia</p>
<p><b>Uncommon</b> (0.1% to 1%): Thrombocytopenia</p>
<p><b>Frequency not reported</b>: Red cell aplasia, congenital neutropenia, myelodysplastic syndrome</p>
<p><b>Postmarketing reports</b>: Pseudomononucleosis, lymphadenopathy, macrocytosis, neutropenia, pancytopenia, agranulocytosis, aplastic anemia, hypoprothrombinemia, methemoglobinemia, megaloblastic (macrocytic) anemia<sup>[Ref]</sup></p><p>Agranulocytosis has generally occurred during the first 1 to 3 months of therapy.  Patients often presented with fever and sore throat.  A few also presented with a rash.  Bone marrow hypoplasia or aplasia was usually confined to the myeloid series, but may be accompanied by erythroid hypoplasia and marrow plasmacytosis.  In one review of 62 cases of sulfasalazine-induced agranulocytosis, 6.5% of patients died.  Recovery of granulocytes was generally seen within 1 to 2 weeks after drug discontinuation, and leukocyte counts and differential returned to normal in 1 to 3 weeks.  Some cases of agranulocytosis were treated with colony stimulating factor, which appeared to increase the time to recovery.<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Cough</p>
<p><b>Uncommon</b> (0.1% to 1%): Dyspnea</p>
<p><b>Frequency not reported</b>: Pulmonary infiltrates (frequently accompanied by eosinophilia), pneumonitis (with or without eosinophilia), pleuritis, bronchiolitis obliterans, lung toxicity (may mimic Wegener's granulomatosis)</p>
<p><b>Postmarketing reports</b>: Oropharyngeal pain, fibrosing alveolitis, eosinophilic infiltration, interstitial lung disease<sup>[Ref]</sup></p><p>Patients often presented after several weeks or months of therapy with fever, malaise, shortness of breath, and nonproductive cough.  Eosinophilic infiltrates have been seen.  Respiratory changes generally resolved over a few weeks, however, fatal reactions involving fibrosing alveolitis have been reported.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Cyanosis</p>
<p><b>Uncommon</b> (0.1% to 1%): Vasculitis</p>
<p><b>Frequency not reported</b>: Tachycardia</p>
<p><b>Postmarketing reports</b>: Myocarditis, allergic myocarditis, pallor, polyarteritis nodosa, pericarditis<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia</p>
<p><b>Uncommon</b> (0.1% to 1%): Depression</p>
<p><b>Frequency not reported</b>: Confusion, vivid dreams</p>
<p><b>Postmarketing reports</b>: Hallucinations<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Arthralgia</p>
<p><b>Frequency not reported</b>: Myopathy, rhabdomyolysis, Sjogren's syndrome</p>
<p><b>Postmarketing reports</b>: Systemic lupus erythematosus</p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fever</p>
<p><b>Uncommon</b> (0.1% to 1%): Facial edema</p>
<p><b>Frequency not reported</b>: Malaise, false positive c-ANCAs, elevated temperature, petechiae and drug fever, LE phenomenon</p>
<p><b>Postmarketing reports</b>: Yellow discoloration of skin and body fluids<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Conjunctival and scleral injection</p>
<p><b>Frequency not reported</b>: Diplopia, blurred vision, corneal damage<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Hypersensitivity reactions, drug-induced rash, lupus erythematosus-like syndrome, anaphylactoid reactions</p>
<p><b>Postmarketing reports</b>: Anaphylaxis, serum sickness<sup>[Ref]</sup></p><p>The following side effects have been reported as hypersensitivity reactions: erythema multiforme (Stevens-Johnson syndrome), exfoliative dermatitis, epidermal necrolysis (Lyell's syndrome) with corneal damage, drug rash with eosinophilia and systemic symptoms (DRESS), anaphylaxis, serum sickness syndrome, pneumonitis (with or without eosinophilia), vasculitis, fibrosing alveolitis, pleuritis, pericarditis (with or without tamponade), allergic myocarditis, polyarteritis nodosa, lupus erythematosus-like syndrome, hepatitis and hepatic necrosis (with or without immune complexes), fulminant hepatitis (sometimes leading to liver transplantation), parapsoriasis varioliformis acuta (Mucha-Haberman syndrome), rhabdomyolysis, photosensitization, arthralgia, periorbital edema, conjunctival and scleral injection, alopecia, and interstitial lung disease.</p>
<p></p>
<p>Anaphylaxis was reported during postmarketing experience with the use of products containing or metabolized to mesalamine.<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Toxic nephrosis with oliguria and anuria, nephritis, hemolytic uremic syndrome, bilateral renal calculi composed of acetylsulfapyridine, proteinase 3-ANCA positive necrotizing glomerulonephritis</p>
<p><b>Postmarketing reports</b>: Nephrolithiasis, nephrotic syndrome, interstitial nephritis<sup>[Ref]</sup></p><p>At least 1 patient developed bilateral renal calculi composed of acetylsulfapyridine, a metabolite of sulfasalazine.<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Rare</b> (less than 0.1%): Goiter production<sup>[Ref]</sup></p><p>Goiter production has been reported rarely in patients using sulfonamides.<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Werlin SL, Grand RJ "Bloody diarrhea--a new complication of sulfasalazine." J Pediatr 92 (1978): 450-1</p><p id="ref_2">2. Ward MM,  Kuzis S "Medication toxicity among patients with ankylosing spondylitis." Arthritis Rheum 47 (2002): 234-41</p><p id="ref_3">3. Marcus RW "Sulfasalazine induced taste disturbances." J Rheumatol 18 (1991): 634-5</p><p id="ref_4">4. Nielsen OH "Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease." Scand J Gastroenterol 17 (1982): 389-93</p><p id="ref_5">5. Mut SE,  Kutlu G,  Ucler S,  Erdal A,  Inan LE "Reversible encephalopathy due to sulfasalazine." Clin Neuropharmacol 31 (2008): 368-71</p><p id="ref_6">6. "Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn, Kalamazoo, MI. </p><p id="ref_7">7. Schwartz AG, Targan SR, Saxon A, Weinstein WM "Sulfasalazine-induced exacerbation of ulcerative colitis." N Engl J Med 306 (1982): 409-12</p><p id="ref_8">8. Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984): 377-86</p><p id="ref_9">9. Faintuch J, Mott CB, Machado MC "Pancreatitis and pancreatic necrosis during sulfasalazine therapy." Int Surg 70 (1985): 271-2</p><p id="ref_10">10. Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994): 789-91</p><p id="ref_11">11. "Drugs for rheumatoid arthritis." Treat Guidel Med Lett 7 (2009): 37-46</p><p id="ref_12">12. Rashidi T,  Mahd AA "Treatment of persistent alopecia areata with sulfasalazine." Int J Dermatol 47 (2008): 850-2</p><p id="ref_13">13. Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983): 833-42</p><p id="ref_14">14. Pokorney BH, Nichols TW, Jr "Pseudomembranous colitis. A complication of sulfasalazine therapy in a patient with Crohn's colitis." Am J Gastroenterol 76 (1981): 374-6</p><p id="ref_15">15. Ring FA, Hershfield NB, Machin GA, Scott RB "Sulfasalazine-induced colitis complicating idiopathic ulcerative colitis." Can Med Assoc J 131 (1984): 43-5</p><p id="ref_16">16. Cantarini L,  Tinazzi I,  Biasi D,  Fioravanti A,  Galeazzi M "Sulfasalazine-induced immune thrombocytopenia." Postgrad Med J 83 (2007): e1</p><p id="ref_17">17. Norden DK, Lichtenstein GR, Williams WV "Sulfasalazine-induced myopathy." Am J Gastroenterol 89 (1994): 801-2</p><p id="ref_18">18. Skeith KJ, Russell AS "Adverse reaction to sulfasalazine." J Rheumatol 15 (1988): 529-30</p><p id="ref_19">19. Alloway JA, Mitchell SR "Sulfasalazine neurotoxicity: a report of aseptic meningitis and a review of the literature." J Rheumatol 20 (1993): 409-11</p><p id="ref_20">20. Schoonjans R, Mast A, Van Den Abeele G, Dewilde D, Achten E, Van Maele V, Pauwels W "Sulfasalazine-associated encephalopathy in a patient with Crohn's disease." Am J Gastroenterol 88 (1993): 1416-20</p><p id="ref_21">21. Olenginski TP, Harrington TM, Carlson JP "Transverse myelitis secondary to sulfasalazine." J Rheumatol 18 (1991): 304</p><p id="ref_22">22. Hill ME, Gordon C, Situnayake RD, Heath DA "Sulfasalazine induced seizures and dysphasia." J Rheumatol 21 (1994): 748-9</p><p id="ref_23">23. Jullien D, Wolkenstein P, Roupie E, Roujeau JC, Revuz J "Toxic epidermal necrolysis after sulfasalazine treatment of mild psoriatic arthritis: warning on the use of sulfasalazine for a new indication." Arthritis Rheum 38 (1995): 573</p><p id="ref_24">24. Pearl RK, Nelson RL, Prasad ML, Orsay CP, Abcarian H "Serious complications of sulfasalazine." Dis Colon Rectum 29 (1986): 201-2</p><p id="ref_25">25. Kaplan S, Mcdonald E, Marino C "Lichen planus in patients with rheumatoid arthritis treated with sulfasalazine." J Rheumatol 22 (1995): 191-2</p><p id="ref_26">26. Clementz GL, Dolin BJ "Sulfasalazine-induced lupus erythematosus." Am J Med 84 (1988): 535-8</p><p id="ref_27">27. Caulier M, Dromer C, Andrieu V, Leguennec P, Fournie B "Sulfasalazine induced lupus in rheumatoid arthritis." J Rheumatol 21 (1994): 750-1</p><p id="ref_28">28. Carr-Locke DL "Sulfasalazine-induced lupus syndrome in a patient with Crohn's disease." Am J Gastroenterol 77 (1982): 614-6</p><p id="ref_29">29. Siam AR, Hammoudeh M "Sulfasalazine induced systemic lupus erythematosus in a patient with rheumatoid arthritis." J Rheumatol 20 (1993): 207</p><p id="ref_30">30. Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986): 193-4,</p><p id="ref_31">31. Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992): 132-5</p><p id="ref_32">32. Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989): 261-3</p><p id="ref_33">33. Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981): 193-8</p><p id="ref_34">34. Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986): 205-8</p><p id="ref_35">35. Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978): 956-8</p><p id="ref_36">36. Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986): 707-8</p><p id="ref_37">37. Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992): 427</p><p id="ref_38">38. Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981): 1070-2</p><p id="ref_39">39. Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984): 401-2</p><p id="ref_40">40. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_41">41. Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978): 95-9</p><p id="ref_42">42. Dery CL, Schwinghammer TL "Agranulocytosis associated with sulfasalazine." Drug Intell Clin Pharm 22 (1988): 139-42</p><p id="ref_43">43. Jick H, Myers MW, Dean AD "The risk of sulfasalazine- and mesalazine-associated blood disorders." Pharmacotherapy 15 (1995): 176-81</p><p id="ref_44">44. Gales BJ, Gales MA "Granulocyte-colony stimulating factor for sulfasalazine-induced agranulocytosis." Ann Pharmacother 27 (1993): 1052-4</p><p id="ref_45">45. Jacobson IM, Kelsey PB, Blyden GT, Demirjian ZN, Isselbacher KJ "Sulfasalazine-induced agranulocytosis." Am J Gastroenterol 80 (1985): 118-21</p><p id="ref_46">46. Kuipers EJ, Vellenga E, de Wolf JT, Hazenberg BP "Sulfasalazine induced agranulocytosis treated with GM-CSF." J Rheumatol 19 (1992): 621-2</p><p id="ref_47">47. Mitrane MP, Singh A, Seibold JR "Cholestasis and fatal agranulocytosis complicating sulfasalazine therapy: case report and review of the literature." J Rheumatol 13 (1986): 969-72</p><p id="ref_48">48. Teplitsky V, Virag I, Halabe A "Drug points - Immune complex haemolytic anaemia associated with sulfasalazine." Br Med J 320 (2000): 1113</p><p id="ref_49">49. Guillemin F, Aussedat R, Guerci A, Lederlin P, Trechot P, Pourel J "Fatal agranulocytosis in sulfasalazine treated rheumatoid arthritis." J Rheumatol 16 (1989): 1166-7</p><p id="ref_50">50. Keisu M, Ekman E "Sulfasalazine associated agranulocytosis in sweden 1972-1989: clinical features, and estimation of its incidence." Eur J Clin Pharmacol 43 (1992): 215-8</p><p id="ref_51">51. Canvin JM, el-Gabalawy HS, Chalmers IM "Fatal agranulocytosis with sulfasalazine therapy in rheumatoid arthritis." J Rheumatol 20 (1993): 909-10</p><p id="ref_52">52. Wheelan KR, Cooper B, Stone MJ "Multiple haematologic abnormalities associated with sulfasalazine." Ann Intern Med 97 (1982): 726-7</p><p id="ref_53">53. Pena JM, Gonzalez-Garcia JJ, Garcia-Alegria J, Barbado FJ, Vazquez JJ "Thrombocytopenia and sulfasalazine." Ann Intern Med 102 (1985): 277-8</p><p id="ref_54">54. Davies GE, Palek J "Selective erythroid and magakaryocytic aplasia after sulfasalazine administration." Arch Intern Med 140 (1980): 1122</p><p id="ref_55">55. Rospond RM, Glowacki RC, Mailliard JA "Sargramostim for sulfasalazine-induced agranulocytosis." Clin Pharm 12 (1993): 179</p><p id="ref_56">56. Mechanick JI "Coombs' positive hemolytic anemia following sulfasalazine therapy in ulcerative colitis: case reports, review, and discussion of pathogenesis." Mt Sinai J Med 52 (1985): 667-70</p><p id="ref_57">57. Youssef PP, Bertouch JV "Sulphasalazine induced aplastic anaemia." Aust N Z J Med 22 (1992): 391-2</p><p id="ref_58">58. Miura N,  Aoyama R,  Kitagawa W,  Yamada H,  Nishikawa K,  Imai H "Proteinase 3-antineutrophil cytoplasmic antibody-(PR3-ANCA) positive necrotizing  glomerulonephritis after restarting sulphasalazine treatment." Clin Nephrol 71 (2009): 74-9</p><p id="ref_59">59. Williams T, Eidus L, Thomas P "Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy." Chest 81 (1982): 766-8</p><p id="ref_60">60. Yaffe BH, Korelitz BI "Sulfasalazine pneumonitis." Am J Gastroenterol 78 (1983): 493-4</p><p id="ref_61">61. Valcke Y, Pauwels R, Van der Straeten M "Bronchoalveolar lavage in acute hypersensitivity pneumonitis caused by sulfasalazine." Chest 92 (1987): 572-3</p><p id="ref_62">62. Sullivan SN "Sulfasalazine lung. Desensitization to sulfasalazine and treatment with acrylic coated 5-ASA and azodisalicylate." J Clin Gastroenterol 9 (1987): 461-3</p><p id="ref_63">63. Wang KK, Bowyer BA, Fleming CR, Schroeder KW "Pulmonary infiltrates and eosinophilia associated with sulfasalazine." Mayo Clin Proc 59 (1984): 343-6</p><p id="ref_64">64. Averbuch M, Halpern Z, Hallak A, Topilsky M, Levo Y "Sulfasalazine pneumonitis." Am J Gastroenterol 80 (1985): 343-5</p><p id="ref_65">65. Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S, Matsumoto K, Kitagawa T, Yamamoto J "Pulmonary infiltrates and skin pigmentation associated with sulfasalazine." Am J Gastroenterol 87 (1992): 1654-7</p><p id="ref_66">66. Baillie J "Sulfasalazine and pulmonary infiltrates." Am J Gastroenterol 79 (1984): 77</p><p id="ref_67">67. Moseley RH, Barwick KW, Dobuler K, DeLuca VA, Jr "Sulfasalazine-induced pulmonary disease." Dig Dis Sci 30 (1985): 901-4</p><p id="ref_68">68. Hamadeh MA, Atkinson J, Smith LJ "Sulfasalazine-induced pulmonary disease." Chest 101 (1992): 1033-7</p><p id="ref_69">69. Kawada A, Kobayashi T, Noguchi H, Hiruma M, Ishibashi A, Marshall J "Fixed drug eruption induced by sulfasalazine." Contact Dermatitis 34 (1996): 155-6</p><p id="ref_70">70. Kounis GN,  Kouni SA,  Chiladakis JA,  Kounis NG "Comment: Mesalamine-Associated Hypersensitivity Myocarditis in Ulcerative Colitis and the Kounis Syndrome (February)." Ann Pharmacother 43 (2009): 393-4</p><p id="ref_71">71. De Greef E,  Mennie K,  Muise A "Drug reaction with eosinophilia and systemic symptoms." CMAJ 182 (2010): 481</p><p id="ref_72">72. Roujeau JC, Kelly JP, Naldi L, et al. "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis." N Engl J Med 333 (1995): 1600-7</p><p id="ref_73">73. Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994): 1605-6</p><p id="ref_74">74. Dwarakanath AD, Michael J, Allan RN "Sulphasalazine-induced renal failure." Gut 33 (1992): 1006-7</p><p id="ref_75">75. Ireland A, Jewell DP "Sulfasalazine-induced impotence: a beneficial resolution with olsalazine?." J Clin Gastroenterol 11 (1989): 711</p><p id="ref_76">76. Chatzinoff M, Guarino JM, Corson SL, Batzer FR, Friedman LS "Sulfasalazine-induced abnormal sperm penetration assay reversed on changing to 5-aminosalicylic acid enemas." Dig Dis Sci 33 (1988): 108-10</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Sulfazine (sulfasalazine)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>10 Reviews</li>
<li>Drug class: 5-aminosalicylates</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Sulfazine &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
<li>Sulfazine EC &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Azulfidine, Azulfidine EN-tabs</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Alopecia</li>
<li>Inflammatory Bowel Disease</li>
<li>Juvenile Rheumatoid Arthritis</li>
<li>Lymphocytic Colitis</li>
<li data-more-config-id="list-data-resources-conditions">... +5 more</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to sulfasalazine: compounding powder, oral delayed release tablet, oral tablet</i></p><h3>General</h3><p>The most common side effects reported were anorexia, headache, nausea, vomiting, gastric distress, elevated temperature, erythema, pruritus, rash, loss of appetite, and reversible oligospermia.  Less common side effects included urticaria, fever, Heinz body anemia, hemolytic anemia, and cyanosis.  Frequency of side effects increased with daily doses of 4 g or more, or total serum sulfapyridine levels above 50 mcg/mL.</p><p></p><p>The use of enteric-coated preparations may decrease gastrointestinal side effects.</p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 33%), vomiting (up to 33%), gastric distress (about 33%), dyspepsia (13%)</p><p><b>Common</b> (1% to 10%): Abdominal pain, diarrhea, stomatitis</p><p><b>Frequency not reported</b>: Impaired folic acid absorption, impaired digoxin absorption, neutropenic enterocolitis, hemorrhagic colitis, bloody diarrhea, necrotizing pancreatitis</p><p><b>Postmarketing reports</b>: Pseudomembranous colitis, pancreatitis, worsening ulcerative colitis, parotitis<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Transverse myelitis developed in 1 patient after receiving sulfasalazine (the active ingredient contained in Sulfazine) for 2 years.  All symptoms resolved within 2 months after discontinuing sulfasalazine.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Headache (up to 33%)</p><p><b>Common</b> (1% to 10%): Dizziness, taste disorders, tinnitus</p><p><b>Uncommon</b> (0.1% to 1%): Convulsions, vertigo</p><p><b>Frequency not reported</b>: Meningitis, neuropathy, transverse myelitis, transient lesions of the posterior spinal column, cauda equina syndrome, Guillain-Barre syndrome, hearing loss, drowsiness, neurotoxicity, dysphasia, acute encephalopathy, monoparesis, cerebrospinal fluid abnormalities, altered taste, peripheral neuritis</p><p><b>Postmarketing reports</b>: Aseptic meningitis, ataxia, encephalopathy, peripheral neuropathy, smell disorders<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Hypoglycemia has been reported rarely in patients using sulfonamides.</p><p><b>Very common</b> (10% or more): Anorexia (about 33%)</p><p><b>Rare</b> (less than 0.1%): Hypoglycemia</p><p><b>Postmarketing reports</b>: Folate deficiency, loss of appetite</p><h3>Genitourinary</h3><p>Diuresis has been reported rarely in patients using sulfonamides.</p><p></p><p>Infertility appeared to be reversible upon drug discontinuation.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Reversible oligospermia (about 33%)</p><p><b>Common</b> (1% to 10%): Proteinuria</p><p><b>Rare</b> (less than 0.1%): Impotence, diuresis</p><p><b>Frequency not reported</b>: Decreased motility, abnormal sperm penetration (sometimes resulted in infertility), urinary tract infections, urine discoloration</p><p><b>Postmarketing reports</b>: Hematuria, crystalluria<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (up to 13%)</p><p><b>Common</b> (1% to 10%): Pruritus, urticaria</p><p><b>Uncommon</b> (0.1% to 1%): Alopecia</p><p><b>Frequency not reported</b>: Toxic epidermal necrolysis (Lyell's syndrome), skin discoloration, erythema multiforme, parapsoriasis varioliformis acuta (Mucha-Haberman syndrome), generalized skin eruptions, petechiae</p><p><b>Postmarketing reports</b>: Angioedema, purpura, epidermal necrolysis (Lyell's syndrome), Stevens-Johnson syndrome, drug rash with eosinophilia and systemic symptoms (DRESS), toxic pustuloderma, erythema, exanthema, exfoliative dermatitis, periorbital edema, lichen planus, photosensitivity<sup>[Ref]</sup></p><p>Angioedema was reported during postmarketing experience with the use of products containing or metabolized to mesalamine.</p><p></p><p>The risk of Stevens-Johnson syndrome or toxic epidermal necrolysis increased largely with the use of sulfonamides; however, these phenomena were rare as a whole.<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Immunoglobulin suppression (10%)</p><p><b>Frequency not reported</b>: Drug-induced systemic lupus erythematosus (SLE)</p><p><b>Postmarketing reports</b>: Kawasaki-like syndrome with hepatic function changes, induction of autoantibodies<sup>[Ref]</sup></p><p>Immunoglobulin suppression was slowly reversible and rarely accompanied by clinical findings.</p><p></p><p>In most cases of sulfasalazine-induced SLE, patients received the drug for greater than 1 year.  Patients most commonly developed arthralgias and pleuritic chest pain.  Generally, these patients had a positive ANA, anti-DNA antibody titer, and were slow acetylators of sulfonamides.  Symptoms typically resolved over several weeks to several months.</p><p></p><p>At least 1 case of Kawasaki-like syndrome with hepatic function changes was reported during postmarketing experience with the use of products containing or metabolized to mesalamine.<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Hepatitis associated with sulfasalazine (the active ingredient contained in Sulfazine) often developed 2 to 4 weeks after therapy was initiated, although hypersensitivity hepatitis has been reported after longer periods of therapy.  Associated rash usually progressed to desquamation.  Liver biopsy has shown necrosis and infiltration with moderate number of inflammatory cells.  Noncaseating granulomas have also been seen.  Hepatitis generally resolved over several weeks after therapy discontinuation, although some patients progressed to fulminant hepatic failure.</p><p></p><p>Hepatitis has been reported in patients with sulfasalazine hypersensitivity.  Some of these cases were fatal.</p><p></p><p>Side effects listed as postmarketing reports were reported during postmarketing experience with the use of products containing or metabolized to mesalamine.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Abnormal liver function tests</p><p><b>Uncommon</b> (0.1% to 1%): Elevated liver enzymes</p><p><b>Frequency not reported</b>: Hepatic necrosis</p><p><b>Postmarketing reports</b>: Hepatotoxicity (some cases were fatal), including elevated liver function tests (SGOT/AST, SGPT/ALT, GGT, LDH, alkaline phosphatase, bilirubin), jaundice, cholestatic jaundice, cirrhosis, cholestatic hepatitis, cholestasis, possible hepatocellular damage (including liver necrosis and liver failure); Kawasaki-like syndrome with hepatic function changes; fulminant hepatitis; hepatitis; hepatic failure<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Hemolytic anemia, Heinz body anemia, leukopenia</p><p><b>Uncommon</b> (0.1% to 1%): Thrombocytopenia</p><p><b>Frequency not reported</b>: Red cell aplasia, congenital neutropenia, myelodysplastic syndrome</p><p><b>Postmarketing reports</b>: Pseudomononucleosis, lymphadenopathy, macrocytosis, neutropenia, pancytopenia, agranulocytosis, aplastic anemia, hypoprothrombinemia, methemoglobinemia, megaloblastic (macrocytic) anemia<sup>[Ref]</sup></p><p>Agranulocytosis has generally occurred during the first 1 to 3 months of therapy.  Patients often presented with fever and sore throat.  A few also presented with a rash.  Bone marrow hypoplasia or aplasia was usually confined to the myeloid series, but may be accompanied by erythroid hypoplasia and marrow plasmacytosis.  In one review of 62 cases of sulfasalazine-induced agranulocytosis, 6.5% of patients died.  Recovery of granulocytes was generally seen within 1 to 2 weeks after drug discontinuation, and leukocyte counts and differential returned to normal in 1 to 3 weeks.  Some cases of agranulocytosis were treated with colony stimulating factor, which appeared to increase the time to recovery.<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Cough</p><p><b>Uncommon</b> (0.1% to 1%): Dyspnea</p><p><b>Frequency not reported</b>: Pulmonary infiltrates (frequently accompanied by eosinophilia), pneumonitis (with or without eosinophilia), pleuritis, bronchiolitis obliterans, lung toxicity (may mimic Wegener's granulomatosis)</p><p><b>Postmarketing reports</b>: Oropharyngeal pain, fibrosing alveolitis, eosinophilic infiltration, interstitial lung disease<sup>[Ref]</sup></p><p>Patients often presented after several weeks or months of therapy with fever, malaise, shortness of breath, and nonproductive cough.  Eosinophilic infiltrates have been seen.  Respiratory changes generally resolved over a few weeks, however, fatal reactions involving fibrosing alveolitis have been reported.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Cyanosis</p><p><b>Uncommon</b> (0.1% to 1%): Vasculitis</p><p><b>Frequency not reported</b>: Tachycardia</p><p><b>Postmarketing reports</b>: Myocarditis, allergic myocarditis, pallor, polyarteritis nodosa, pericarditis<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia</p><p><b>Uncommon</b> (0.1% to 1%): Depression</p><p><b>Frequency not reported</b>: Confusion, vivid dreams</p><p><b>Postmarketing reports</b>: Hallucinations<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Arthralgia</p><p><b>Frequency not reported</b>: Myopathy, rhabdomyolysis, Sjogren's syndrome</p><p><b>Postmarketing reports</b>: Systemic lupus erythematosus</p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fever</p><p><b>Uncommon</b> (0.1% to 1%): Facial edema</p><p><b>Frequency not reported</b>: Malaise, false positive c-ANCAs, elevated temperature, petechiae and drug fever, LE phenomenon</p><p><b>Postmarketing reports</b>: Yellow discoloration of skin and body fluids<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Conjunctival and scleral injection</p><p><b>Frequency not reported</b>: Diplopia, blurred vision, corneal damage<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Hypersensitivity reactions, drug-induced rash, lupus erythematosus-like syndrome, anaphylactoid reactions</p><p><b>Postmarketing reports</b>: Anaphylaxis, serum sickness<sup>[Ref]</sup></p><p>The following side effects have been reported as hypersensitivity reactions: erythema multiforme (Stevens-Johnson syndrome), exfoliative dermatitis, epidermal necrolysis (Lyell's syndrome) with corneal damage, drug rash with eosinophilia and systemic symptoms (DRESS), anaphylaxis, serum sickness syndrome, pneumonitis (with or without eosinophilia), vasculitis, fibrosing alveolitis, pleuritis, pericarditis (with or without tamponade), allergic myocarditis, polyarteritis nodosa, lupus erythematosus-like syndrome, hepatitis and hepatic necrosis (with or without immune complexes), fulminant hepatitis (sometimes leading to liver transplantation), parapsoriasis varioliformis acuta (Mucha-Haberman syndrome), rhabdomyolysis, photosensitization, arthralgia, periorbital edema, conjunctival and scleral injection, alopecia, and interstitial lung disease.</p><p></p><p>Anaphylaxis was reported during postmarketing experience with the use of products containing or metabolized to mesalamine.<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Toxic nephrosis with oliguria and anuria, nephritis, hemolytic uremic syndrome, bilateral renal calculi composed of acetylsulfapyridine, proteinase 3-ANCA positive necrotizing glomerulonephritis</p><p><b>Postmarketing reports</b>: Nephrolithiasis, nephrotic syndrome, interstitial nephritis<sup>[Ref]</sup></p><p>At least 1 patient developed bilateral renal calculi composed of acetylsulfapyridine, a metabolite of sulfasalazine.<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Rare</b> (less than 0.1%): Goiter production<sup>[Ref]</sup></p><p>Goiter production has been reported rarely in patients using sulfonamides.<sup>[Ref]</sup></p><p id="ref_1">1. Werlin SL, Grand RJ "Bloody diarrhea--a new complication of sulfasalazine." J Pediatr 92 (1978): 450-1</p><p id="ref_2">2. Ward MM,  Kuzis S "Medication toxicity among patients with ankylosing spondylitis." Arthritis Rheum 47 (2002): 234-41</p><p id="ref_3">3. Marcus RW "Sulfasalazine induced taste disturbances." J Rheumatol 18 (1991): 634-5</p><p id="ref_4">4. Nielsen OH "Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease." Scand J Gastroenterol 17 (1982): 389-93</p><p id="ref_5">5. Mut SE,  Kutlu G,  Ucler S,  Erdal A,  Inan LE "Reversible encephalopathy due to sulfasalazine." Clin Neuropharmacol 31 (2008): 368-71</p><p id="ref_6">6. "Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn, Kalamazoo, MI. </p><p id="ref_7">7. Schwartz AG, Targan SR, Saxon A, Weinstein WM "Sulfasalazine-induced exacerbation of ulcerative colitis." N Engl J Med 306 (1982): 409-12</p><p id="ref_8">8. Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984): 377-86</p><p id="ref_9">9. Faintuch J, Mott CB, Machado MC "Pancreatitis and pancreatic necrosis during sulfasalazine therapy." Int Surg 70 (1985): 271-2</p><p id="ref_10">10. Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994): 789-91</p><p id="ref_11">11. "Drugs for rheumatoid arthritis." Treat Guidel Med Lett 7 (2009): 37-46</p><p id="ref_12">12. Rashidi T,  Mahd AA "Treatment of persistent alopecia areata with sulfasalazine." Int J Dermatol 47 (2008): 850-2</p><p id="ref_13">13. Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983): 833-42</p><p id="ref_14">14. Pokorney BH, Nichols TW, Jr "Pseudomembranous colitis. A complication of sulfasalazine therapy in a patient with Crohn's colitis." Am J Gastroenterol 76 (1981): 374-6</p><p id="ref_15">15. Ring FA, Hershfield NB, Machin GA, Scott RB "Sulfasalazine-induced colitis complicating idiopathic ulcerative colitis." Can Med Assoc J 131 (1984): 43-5</p><p id="ref_16">16. Cantarini L,  Tinazzi I,  Biasi D,  Fioravanti A,  Galeazzi M "Sulfasalazine-induced immune thrombocytopenia." Postgrad Med J 83 (2007): e1</p><p id="ref_17">17. Norden DK, Lichtenstein GR, Williams WV "Sulfasalazine-induced myopathy." Am J Gastroenterol 89 (1994): 801-2</p><p id="ref_18">18. Skeith KJ, Russell AS "Adverse reaction to sulfasalazine." J Rheumatol 15 (1988): 529-30</p><p id="ref_19">19. Alloway JA, Mitchell SR "Sulfasalazine neurotoxicity: a report of aseptic meningitis and a review of the literature." J Rheumatol 20 (1993): 409-11</p><p id="ref_20">20. Schoonjans R, Mast A, Van Den Abeele G, Dewilde D, Achten E, Van Maele V, Pauwels W "Sulfasalazine-associated encephalopathy in a patient with Crohn's disease." Am J Gastroenterol 88 (1993): 1416-20</p><p id="ref_21">21. Olenginski TP, Harrington TM, Carlson JP "Transverse myelitis secondary to sulfasalazine." J Rheumatol 18 (1991): 304</p><p id="ref_22">22. Hill ME, Gordon C, Situnayake RD, Heath DA "Sulfasalazine induced seizures and dysphasia." J Rheumatol 21 (1994): 748-9</p><p id="ref_23">23. Jullien D, Wolkenstein P, Roupie E, Roujeau JC, Revuz J "Toxic epidermal necrolysis after sulfasalazine treatment of mild psoriatic arthritis: warning on the use of sulfasalazine for a new indication." Arthritis Rheum 38 (1995): 573</p><p id="ref_24">24. Pearl RK, Nelson RL, Prasad ML, Orsay CP, Abcarian H "Serious complications of sulfasalazine." Dis Colon Rectum 29 (1986): 201-2</p><p id="ref_25">25. Kaplan S, Mcdonald E, Marino C "Lichen planus in patients with rheumatoid arthritis treated with sulfasalazine." J Rheumatol 22 (1995): 191-2</p><p id="ref_26">26. Clementz GL, Dolin BJ "Sulfasalazine-induced lupus erythematosus." Am J Med 84 (1988): 535-8</p><p id="ref_27">27. Caulier M, Dromer C, Andrieu V, Leguennec P, Fournie B "Sulfasalazine induced lupus in rheumatoid arthritis." J Rheumatol 21 (1994): 750-1</p><p id="ref_28">28. Carr-Locke DL "Sulfasalazine-induced lupus syndrome in a patient with Crohn's disease." Am J Gastroenterol 77 (1982): 614-6</p><p id="ref_29">29. Siam AR, Hammoudeh M "Sulfasalazine induced systemic lupus erythematosus in a patient with rheumatoid arthritis." J Rheumatol 20 (1993): 207</p><p id="ref_30">30. Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986): 193-4,</p><p id="ref_31">31. Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992): 132-5</p><p id="ref_32">32. Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989): 261-3</p><p id="ref_33">33. Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981): 193-8</p><p id="ref_34">34. Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986): 205-8</p><p id="ref_35">35. Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978): 956-8</p><p id="ref_36">36. Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986): 707-8</p><p id="ref_37">37. Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992): 427</p><p id="ref_38">38. Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981): 1070-2</p><p id="ref_39">39. Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984): 401-2</p><p id="ref_40">40. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_41">41. Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978): 95-9</p><p id="ref_42">42. Dery CL, Schwinghammer TL "Agranulocytosis associated with sulfasalazine." Drug Intell Clin Pharm 22 (1988): 139-42</p><p id="ref_43">43. Jick H, Myers MW, Dean AD "The risk of sulfasalazine- and mesalazine-associated blood disorders." Pharmacotherapy 15 (1995): 176-81</p><p id="ref_44">44. Gales BJ, Gales MA "Granulocyte-colony stimulating factor for sulfasalazine-induced agranulocytosis." Ann Pharmacother 27 (1993): 1052-4</p><p id="ref_45">45. Jacobson IM, Kelsey PB, Blyden GT, Demirjian ZN, Isselbacher KJ "Sulfasalazine-induced agranulocytosis." Am J Gastroenterol 80 (1985): 118-21</p><p id="ref_46">46. Kuipers EJ, Vellenga E, de Wolf JT, Hazenberg BP "Sulfasalazine induced agranulocytosis treated with GM-CSF." J Rheumatol 19 (1992): 621-2</p><p id="ref_47">47. Mitrane MP, Singh A, Seibold JR "Cholestasis and fatal agranulocytosis complicating sulfasalazine therapy: case report and review of the literature." J Rheumatol 13 (1986): 969-72</p><p id="ref_48">48. Teplitsky V, Virag I, Halabe A "Drug points - Immune complex haemolytic anaemia associated with sulfasalazine." Br Med J 320 (2000): 1113</p><p id="ref_49">49. Guillemin F, Aussedat R, Guerci A, Lederlin P, Trechot P, Pourel J "Fatal agranulocytosis in sulfasalazine treated rheumatoid arthritis." J Rheumatol 16 (1989): 1166-7</p><p id="ref_50">50. Keisu M, Ekman E "Sulfasalazine associated agranulocytosis in sweden 1972-1989: clinical features, and estimation of its incidence." Eur J Clin Pharmacol 43 (1992): 215-8</p><p id="ref_51">51. Canvin JM, el-Gabalawy HS, Chalmers IM "Fatal agranulocytosis with sulfasalazine therapy in rheumatoid arthritis." J Rheumatol 20 (1993): 909-10</p><p id="ref_52">52. Wheelan KR, Cooper B, Stone MJ "Multiple haematologic abnormalities associated with sulfasalazine." Ann Intern Med 97 (1982): 726-7</p><p id="ref_53">53. Pena JM, Gonzalez-Garcia JJ, Garcia-Alegria J, Barbado FJ, Vazquez JJ "Thrombocytopenia and sulfasalazine." Ann Intern Med 102 (1985): 277-8</p><p id="ref_54">54. Davies GE, Palek J "Selective erythroid and magakaryocytic aplasia after sulfasalazine administration." Arch Intern Med 140 (1980): 1122</p><p id="ref_55">55. Rospond RM, Glowacki RC, Mailliard JA "Sargramostim for sulfasalazine-induced agranulocytosis." Clin Pharm 12 (1993): 179</p><p id="ref_56">56. Mechanick JI "Coombs' positive hemolytic anemia following sulfasalazine therapy in ulcerative colitis: case reports, review, and discussion of pathogenesis." Mt Sinai J Med 52 (1985): 667-70</p><p id="ref_57">57. Youssef PP, Bertouch JV "Sulphasalazine induced aplastic anaemia." Aust N Z J Med 22 (1992): 391-2</p><p id="ref_58">58. Miura N,  Aoyama R,  Kitagawa W,  Yamada H,  Nishikawa K,  Imai H "Proteinase 3-antineutrophil cytoplasmic antibody-(PR3-ANCA) positive necrotizing  glomerulonephritis after restarting sulphasalazine treatment." Clin Nephrol 71 (2009): 74-9</p><p id="ref_59">59. Williams T, Eidus L, Thomas P "Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy." Chest 81 (1982): 766-8</p><p id="ref_60">60. Yaffe BH, Korelitz BI "Sulfasalazine pneumonitis." Am J Gastroenterol 78 (1983): 493-4</p><p id="ref_61">61. Valcke Y, Pauwels R, Van der Straeten M "Bronchoalveolar lavage in acute hypersensitivity pneumonitis caused by sulfasalazine." Chest 92 (1987): 572-3</p><p id="ref_62">62. Sullivan SN "Sulfasalazine lung. Desensitization to sulfasalazine and treatment with acrylic coated 5-ASA and azodisalicylate." J Clin Gastroenterol 9 (1987): 461-3</p><p id="ref_63">63. Wang KK, Bowyer BA, Fleming CR, Schroeder KW "Pulmonary infiltrates and eosinophilia associated with sulfasalazine." Mayo Clin Proc 59 (1984): 343-6</p><p id="ref_64">64. Averbuch M, Halpern Z, Hallak A, Topilsky M, Levo Y "Sulfasalazine pneumonitis." Am J Gastroenterol 80 (1985): 343-5</p><p id="ref_65">65. Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S, Matsumoto K, Kitagawa T, Yamamoto J "Pulmonary infiltrates and skin pigmentation associated with sulfasalazine." Am J Gastroenterol 87 (1992): 1654-7</p><p id="ref_66">66. Baillie J "Sulfasalazine and pulmonary infiltrates." Am J Gastroenterol 79 (1984): 77</p><p id="ref_67">67. Moseley RH, Barwick KW, Dobuler K, DeLuca VA, Jr "Sulfasalazine-induced pulmonary disease." Dig Dis Sci 30 (1985): 901-4</p><p id="ref_68">68. Hamadeh MA, Atkinson J, Smith LJ "Sulfasalazine-induced pulmonary disease." Chest 101 (1992): 1033-7</p><p id="ref_69">69. Kawada A, Kobayashi T, Noguchi H, Hiruma M, Ishibashi A, Marshall J "Fixed drug eruption induced by sulfasalazine." Contact Dermatitis 34 (1996): 155-6</p><p id="ref_70">70. Kounis GN,  Kouni SA,  Chiladakis JA,  Kounis NG "Comment: Mesalamine-Associated Hypersensitivity Myocarditis in Ulcerative Colitis and the Kounis Syndrome (February)." Ann Pharmacother 43 (2009): 393-4</p><p id="ref_71">71. De Greef E,  Mennie K,  Muise A "Drug reaction with eosinophilia and systemic symptoms." CMAJ 182 (2010): 481</p><p id="ref_72">72. Roujeau JC, Kelly JP, Naldi L, et al. "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis." N Engl J Med 333 (1995): 1600-7</p><p id="ref_73">73. Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994): 1605-6</p><p id="ref_74">74. Dwarakanath AD, Michael J, Allan RN "Sulphasalazine-induced renal failure." Gut 33 (1992): 1006-7</p><p id="ref_75">75. Ireland A, Jewell DP "Sulfasalazine-induced impotence: a beneficial resolution with olsalazine?." J Clin Gastroenterol 11 (1989): 711</p><p id="ref_76">76. Chatzinoff M, Guarino JM, Corson SL, Batzer FR, Friedman LS "Sulfasalazine-induced abnormal sperm penetration assay reversed on changing to 5-aminosalicylic acid enemas." Dig Dis Sci 33 (1988): 108-10</p><h2>More about Sulfazine (sulfasalazine)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>10 Reviews</li>
<li>Drug class: 5-aminosalicylates</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Sulfazine &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
<li>Sulfazine EC &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Alopecia</li>
<li>Inflammatory Bowel Disease</li>
<li>Juvenile Rheumatoid Arthritis</li>
<li>Lymphocytic Colitis</li>
<li data-more-config-id="list-data-resources-conditions">... +5 more</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>